JP2021506817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506817A5 JP2021506817A5 JP2020532892A JP2020532892A JP2021506817A5 JP 2021506817 A5 JP2021506817 A5 JP 2021506817A5 JP 2020532892 A JP2020532892 A JP 2020532892A JP 2020532892 A JP2020532892 A JP 2020532892A JP 2021506817 A5 JP2021506817 A5 JP 2021506817A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- day
- treatment cycle
- administered
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207423 | 2017-12-14 | ||
| EP17207423.9 | 2017-12-14 | ||
| EP18160044.6 | 2018-03-05 | ||
| EP18160044 | 2018-03-05 | ||
| PCT/EP2018/084652 WO2019115659A1 (en) | 2017-12-14 | 2018-12-13 | Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506817A JP2021506817A (ja) | 2021-02-22 |
| JP2021506817A5 true JP2021506817A5 (https=) | 2022-01-11 |
Family
ID=64607022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532892A Pending JP2021506817A (ja) | 2017-12-14 | 2018-12-13 | がんを治療するための投与計画におけるｃｅａ ｃｄ３二重特異性抗体及びｐｄ−１軸結合アンタゴニストの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200407450A1 (https=) |
| EP (1) | EP3723799A1 (https=) |
| JP (1) | JP2021506817A (https=) |
| KR (1) | KR20200099135A (https=) |
| CN (1) | CN111212660A (https=) |
| AU (1) | AU2018382966A1 (https=) |
| CA (1) | CA3079039A1 (https=) |
| IL (1) | IL275225A (https=) |
| MX (1) | MX2020006125A (https=) |
| TW (1) | TW201934578A (https=) |
| WO (1) | WO2019115659A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180097615A (ko) * | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| WO2021053587A1 (en) | 2019-09-18 | 2021-03-25 | Klaus Strein | Bispecific antibodies against ceacam5 and cd3 |
| PE20230835A1 (es) * | 2020-06-19 | 2023-05-19 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
| CN115916830A (zh) * | 2020-06-25 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 抗cd3/抗cd28双特异性抗原结合分子 |
| AU2024317606A1 (en) * | 2023-07-29 | 2026-02-26 | Chimagen Biosciences, Ltd | Modified type e multi-specific antibodies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| RS54655B2 (sr) | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| KR20180097615A (ko) * | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
-
2018
- 2018-12-13 KR KR1020207015873A patent/KR20200099135A/ko not_active Ceased
- 2018-12-13 AU AU2018382966A patent/AU2018382966A1/en not_active Abandoned
- 2018-12-13 CN CN201880066731.2A patent/CN111212660A/zh active Pending
- 2018-12-13 CA CA3079039A patent/CA3079039A1/en active Pending
- 2018-12-13 WO PCT/EP2018/084652 patent/WO2019115659A1/en not_active Ceased
- 2018-12-13 MX MX2020006125A patent/MX2020006125A/es unknown
- 2018-12-13 JP JP2020532892A patent/JP2021506817A/ja active Pending
- 2018-12-13 EP EP18814941.3A patent/EP3723799A1/en not_active Withdrawn
- 2018-12-13 TW TW107145062A patent/TW201934578A/zh unknown
-
2020
- 2020-06-08 IL IL275225A patent/IL275225A/en unknown
- 2020-06-10 US US16/898,248 patent/US20200407450A1/en not_active Abandoned